Open Access
- 25 January 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 710
Abstract
Blepharitis is a common chronic inflammatory condition affecting the eyelid margins; the pathophysiology of blepharitis is complex and not fully understood. The disease is anatomically divided into anterior (inflammation of eyelashes) and posterior (meibomian gland dysfunction) types. Diagnosis relies on clinical examination, revealing characteristic features like scurf, vascular changes, and meibomian gland dysfunction. The main goals of blepharitis treatment are symptom relief, recurrence prevention, and complication risk minimization. Treatment options include lid hygiene, topical and systemic antibiotics, topical corticosteroids, and omega-3 supplements. However, it is important to highlight reported cases of blepharitis as side effects of systemic therapies, particularly in the context of chemotherapy, bortezomib, cetuximab, TNFα inhibitors, and dupilumab. It is crucial to monitor patients undergoing such treatments regularly and attentively in order to promptly set up adequate supportive therapy. Of even more importance is future research on the pathophysiological mechanisms responsible for the occurrence of these ocular side effects in order to find a nosological cure for the issue.Keywords
Funding Information
- Théa Farma SpA
This publication has 47 references indexed in Scilit:
- Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis SiccaCornea, 2013
- Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year reviewSupportive Care in Cancer, 2012
- Meibomitis-Related KeratoconjunctivitisCornea, 2012
- Interventions for chronic blepharitisCochrane Database of Systematic Reviews, 2012
- The International Workshop on Meibomian Gland Dysfunction: Executive SummaryInvestigative Ophthalmology & Visual Science, 2011
- BlepharitisSeminars in Ophthalmology, 2010
- Topical ciclosporin in the treatment of ocular surface disordersBritish Journal of Ophthalmology, 2005
- Ocular Toxicity Related to Cetuximab Monotherapy in an Advanced Colorectal Cancer PatientJNCI: Journal of the National Cancer Institute, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Ocular complications of systemic cancer chemotherapySurvey of Ophthalmology, 1989